Back to Search Start Over

Abstract A04: Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia

Authors :
Eric Wang
Omar Abdel-Wahab
Robert K Bradley
Jose Mario Bello
Won Jun Kim
Carine Bossard
Source :
Blood Cancer Discovery. 4:A04-A04
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Therapy resistance is a major challenge in the treatment of cancer. Here, we performed CRISPR/Cas9 screens across a broad range of therapies used in acute myeloid leukemia to identify genomic determinants of drug response. Our screens uncovered a selective dependency on RNA splicing factors whose loss preferentially enhanced response to the BCL2 inhibitor venetoclax. Loss of the splicing factor RBM10 augmented response to venetoclax in leukemia yet was completely dispensable for normal hematopoiesis. Combined RBM10 and BCL2 inhibition led to mis-splicing and inactivation of the inhibitor of apoptosis XIAP and downregulation of BCL2A1, an anti-apoptotic protein implicated in venetoclax resistance. A novel inhibitor of splicing kinase families CLKs and DYRKs led to aberrant splicing of key splicing and apoptotic factors that synergized with venetoclax and overcame resistance to BCL2 inhibition. Our findings underscore the importance of splicing in modulating response to therapies and provide a strategy to improve venetoclax-based treatments. Citation Format: Eric Wang, Omar Abdel-Wahab, Robert K Bradley, Jose Mario Bello, Won Jun Kim, Carine Bossard. Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia [abstract]. In: Proceedings of the AACR Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome; 2023 Jan 23-25; Austin, TX. Philadelphia (PA): AACR; Blood Cancer Discov 2023;4(3_Suppl):Abstract nr A04.

Subjects

Subjects :
General Medicine

Details

ISSN :
26433249
Volume :
4
Database :
OpenAIRE
Journal :
Blood Cancer Discovery
Accession number :
edsair.doi...........fb117fe2ecbd96d060289241cd4b5941